A Phase 1b, Open-label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination With Anti-PD-1 (Pembrolizumab) for Patients With Locally Advanced or Metastatic Melanoma, Locally Advanced or Metastatic Urothelial Bladder Cancer, or Metastatic Non-Small Cell Lung Cancer or NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer or Metastatic Non-Small Cell Lung Cancer

Trial Profile

A Phase 1b, Open-label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination With Anti-PD-1 (Pembrolizumab) for Patients With Locally Advanced or Metastatic Melanoma, Locally Advanced or Metastatic Urothelial Bladder Cancer, or Metastatic Non-Small Cell Lung Cancer or NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer or Metastatic Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Atezolizumab (Primary) ; NKTR 214 (Primary) ; Pembrolizumab (Primary)
  • Indications Bladder cancer; Malignant melanoma; Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms PROPEL
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 09 Nov 2017 Planned End Date changed from 30 May 2020 to 1 May 2020.
    • 09 Nov 2017 Planned primary completion date changed from 30 May 2018 to 1 Dec 2018.
    • 12 Sep 2017 According to an Nektar Therapeutics media release, dosing has begun in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top